Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults

In 2014, the Advisory Committee on Immunization Practices recommended routine use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults age ≥ 65 years. Incidence of most PCV13-serotype cases declined, however serotype 3 cases have persisted. We estimated PCV13 vaccine effectiveness (VE)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2025-01, Vol.44, p.126543, Article 126543
Hauptverfasser:	Hsiao, Amber, Lewis, Ned, Hansen, John, Timbol, Julius, Suaya, Jose A., Alexander-Parrish, Ronika, Grant, Lindsay R., Gessner, Bradford D., Klein, Nicola P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Age Aged Aged, 80 and over California California - epidemiology Cardiovascular disease Chronic illnesses Chronic obstructive pulmonary disease Cohort analysis Conjugates Diabetes Effectiveness Female health services Humans Immunization Incidence Influenza influenza vaccines Invasive pneumococcal disease Male monitoring nationalities and ethnic groups Observational studies odds ratio Older people Pediatrics Pneumococcal Infections - epidemiology Pneumococcal Infections - immunology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - immunology Pneumonia Polysaccharides Population Population studies regression analysis risk Risk factors Serogroup Serotypes Service areas Streptococcus infections Streptococcus pneumoniae Streptococcus pneumoniae - classification Streptococcus pneumoniae - immunology Surveillance vaccination Vaccination - statistics & numerical data Vaccine effectiveness Vaccine efficacy Vaccine Efficacy - statistics & numerical data Vaccines Vaccines, Conjugate - administration & dosage Vaccines, Conjugate - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!